Engineered Stem Cell Therapy Reverses Type 1 Diabetes in Mice, Boosting 2 Key Immune Shifts
Updated
Updated · SciTechDaily · Jul 7
Engineered Stem Cell Therapy Reverses Type 1 Diabetes in Mice, Boosting 2 Key Immune Shifts
1 articles · Updated · SciTechDaily · Jul 7
Summary
MUSC researchers reversed newly diagnosed Type 1 diabetes in mice with engineered mesenchymal stem cells that target the disease’s autoimmune cause rather than only controlling blood sugar.
AAT-MSCs were modified to produce alpha-1 antitrypsin, helping the cells withstand inflammation while protecting remaining insulin-producing pancreatic cells and damping the immune attack against them.
Thousands of immune cells analyzed after infusion showed a rise in regulatory T cells and a drop in active CD8+ killer T cells, with the attacking cells appearing to enter exhaustion.
The stem cells cleared within hours to days, but the immune reset persisted, suggesting a durable effect that Wang said could last 6 months to 2 years based on MSC trials in other diseases.
The team is now testing MSCs in patients with newly diagnosed Type 1 diabetes and says the immune-reprogramming approach could also extend to lupus, chronic pancreatitis and longer-term T1D.
A new therapy’s cells vanish in days, but its effects last. Is this the key to a permanent diabetes cure?
With rival drugs already approved, can this transient stem cell therapy offer a safer, more effective diabetes solution?
The 2026 State of Stem Cell Therapy for Type 1 Diabetes: From Immune Evasion to Clinical Impact
Overview
Recent breakthroughs in stem cell therapy are transforming the treatment of Type 1 Diabetes (T1D). Cutting-edge research from late 2025 and early 2026 has led to innovative strategies such as immune reprogramming, immune evasion, and hybrid immune systems. These approaches offer new hope by targeting the root causes of T1D, not just its symptoms. For example, scientists at MUSC developed a genetically enhanced stem cell therapy that reversed new-onset diabetes in mice by reprogramming the immune system to stop attacking insulin-producing cells. These advances mark a major step toward lasting solutions for people living with T1D.